GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC
NCT03417882
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
20
Enrollment
INDUSTRY
Sponsor class
Stopped
Recruitment rate too slow
Conditions
Metastatic NSCLC
Interventions
BIOLOGICAL:
GRN-1201 + Pembrolizumab
Sponsor
BrightPath Biotherapeutics